10 Best Weight Loss Drug Stocks to Buy in 2026
The anti-obesity drug (AOM) market in the United States is rapidly changing structurally.
Altimmune Inc. (ALT)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Marshall Wace LLP Paul Marshall And Ian Wace | 4,017,901 | $12,375,135 | +336% | 0.01% |
| 2. | Millennium Management Israel Englander | 3,258,191 | $10,035,228 | +1472% | 0% |
| 3. | Alyeska Investment Group Anand Parekh | 2,644,600 | $8,145,368 | 0.02% | |
| 4. | Two Sigma Advisors John Overdeck And David Siegel | 2,478,900 | $7,635,012 | +213% | 0.01% |
| 5. | D E Shaw D. E. Shaw | 727,001 | $2,239,163 | -46% | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $3.41 | 9,200 | $31,349.92 | 21,700 | 2026-04-06 | Filing | |
| $3.15 | 10,000 | $31,499.00 | 38,078 | 2026-04-01 | Filing | |
| $3.14 | 15,000 | $47,100.00 | 47,500 | 2026-04-01 | Filing | |
| $3.54 | 5,000 | $17,700.00 | 28,078 | 2026-03-06 | Filing | |
| $3.54 | 20,000 | $70,790.00 | 32,500 | 2026-03-06 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $6.88 | 8,184 | $56,305.92 | 55,524 | 2024-08-19 | Filing | |
| $6.93 | 7,827 | $54,241.11 | 41,958 | 2024-08-19 | Filing | |
| $15.00 | 2,714 | $40,710.00 | 2,771 | 2022-08-12 | Filing | |
| $15.01 | 20,000 | $300,268.00 | 8,498 | 2022-12-22 | Filing | |
| $20.02 | 20,000 | $400,322.00 | 236,797 | 2022-08-31 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 12,795,277 | $39,409,453 | 0% | |
| 2. | 7,145,550 | $22,008,294 | 0% | |
| 3. | 5,658,049 | $17,426,791 | 0% | |
| 4. | 5,382,002 | $16,576,566 | 0% | |
| 5. | 3,107,096 | $9,572,306 | 0% |
News See All
10 Small Cap Stocks with Potential to Rise 1000 Percent
Small-cap stocks have returned to the market’s risk conversation in 2026.
Altimmune, Inc. (NASDAQ:ALT) Q1 2026 Earnings Call Transcript
Operator: Good morning, ladies and gentlemen, and welcome to the Altimmune First Quarter 2026 Financial Results Conference Call. [Operator Instructions] As a reminder, this call is being recorded.
10 Most Shorted Penny Stocks to Buy
In this article, we will take a look at some of the most shorted penny stocks that currently appear highly attractive with impressive upside potential.
H.C. Wainwright Bullish on Altimmune (ALT) Amid Growing Focus on Treatments for Metabolic and Liver Diseases
On March 16, 2026, H.C. Wainwright noted growing optimism around pipeline expansion and upside potential by raising the price target for Altimmune, Inc.
Top 10 Stocks Under $5 That Could Triple
At one end of the spectrum, until a few weeks ago, there was optimism about the broader market's performance this year.
Altimmune, Inc. (NASDAQ:ALT) Q4 2025 Earnings Call Transcript
Operator: Good morning, ladies and gentlemen, and welcome to the Altimmune, Inc. year-end 2025 financial results conference call.
Altimmune, Inc. (ALT) Gains Analyst Support as Pemvidutide Advances
Altimmune, Inc. (NASDAQ:ALT) is one of the best high-return penny stocks to buy right now. On February 13, Titan Partners initiated coverage of Altimmune, Inc.
11 Best High Return Penny Stocks to Buy Right Now
Small-cap companies are in the spotlight amid market rotation away from technology heavyweights clobbered by premium valuation.
Altimmune, Inc. (ALT) Gains Analyst Support Ahead of Phase 3 MASH Development
TheFly reported on January 27 that Barclays initiated coverage of ALT with an Overweight rating and a $20 price target.
Hedge Fund Resource Center